Tech Company Financing Transactions
Charm Therapeutics Funding Round
Charm Therapeutics, based in London England, secured $50 million from F-Prime Capital, OrbiMed and Axial.
Transaction Overview
Company Name
Announced On
6/10/2022
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series A
Investors
F-Prime Capital (Lead Investor)
OrbiMed (Lead Investor)
Proceeds Purpose
The capital is slated to be used to further the company's ambitions of transforming structure-based drug discovery, namely via its proprietary "DragonFold AI" technology.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7 Pancras Sq
London England, N1C 4AG
UK
London England, N1C 4AG
UK
Phone
Undisclosed
Website
Email Address
Overview
Founded by leaders with a track record in next-wave AI, with a culture of excellence and innovation at its heart and a commitment to delivery. We are an entrepreneurial team of extraordinary scientists, engineers and entrepreneurs, purpose-built to meld cutting edge know-how from 3D deep learning and drug discovery.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Laksh Aithani
Co-Founder
David Baker
Browse more venture capital transactions:
Prev: 6/10/2022: Flare venture capital transaction
Next: 6/10/2022: Boulder Care venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs